AAPL342.92-0.55 (-0.16%) ▼|ABBV284.42-1.00 (-0.35%) ▼|ABT103.77-1.12 (-1.07%) ▼|ACN231.93+2.25 (+0.98%) ▲|ADBE244.88-0.33 (-0.13%) ▼|AMAT423.98+14.69 (+3.59%) ▲|AMD548.48+19.73 (+3.73%) ▲|AMGN427.01-5.49 (-1.27%) ▼|AMT182.77-2.50 (-1.35%) ▼|AMZN262.97+12.97 (+5.19%) ▲|AVGO339.14+10.39 (+3.16%) ▲|AXP313.39-0.21 (-0.07%) ▼|BA191.44+1.23 (+0.64%) ▲|BAC50.53-0.71 (-1.38%) ▼|BKNG161.04-2.41 (-1.47%) ▼|BLK1,128.55-5.83 (-0.51%) ▼|BMY58.66-1.10 (-1.83%) ▼|BNY143.11-0.20 (-0.14%) ▼|BRK-B530.62-1.41 (-0.26%) ▼|C122.91-1.35 (-1.09%) ▼|CAT730.66-0.10 (-0.01%) ▼|CL93.04-1.07 (-1.14%) ▼|CMCSA21.72-0.19 (-0.84%) ▼|COF199.66-2.08 (-1.03%) ▼|COP144.69-1.82 (-1.24%) ▼|COST990.00+0.89 (+0.09%) ▲|CRM239.54-1.16 (-0.48%) ▼|CSCO107.35-0.04 (-0.04%) ▼|CVS91.22-1.14 (-1.23%) ▼|CVX223.64-1.35 (-0.60%) ▼|DE629.94-11.92 (-1.86%) ▼|DHR225.22-3.82 (-1.67%) ▼|DIS109.71-0.89 (-0.80%) ▼|DUK119.56-1.92 (-1.58%) ▼|EMR161.73+0.26 (+0.16%) ▲|FDX292.88-0.67 (-0.23%) ▼|GD341.62-2.61 (-0.76%) ▼|GE312.35-1.48 (-0.47%) ▼|GEV921.84+0.64 (+0.07%) ▲|GILD154.68-1.51 (-0.97%) ▼|GM82.42-1.54 (-1.83%) ▼|GOOG341.25+4.34 (+1.29%) ▲|GOOGL345.42+4.83 (+1.42%) ▲|GS881.36+0.10 (+0.01%) ▲|HD309.40-0.23 (-0.07%) ▼|HON211.09-0.33 (-0.15%) ▼|IBM236.12+3.98 (+1.71%) ▲|INTC94.58+4.73 (+5.26%) ▲|INTU321.82-3.33 (-1.02%) ▼|ISRG432.22+5.52 (+1.29%) ▲|JNJ252.70-2.86 (-1.12%) ▼|JPM335.60-4.12 (-1.21%) ▼|KO93.60-0.30 (-0.32%) ▼|LIN501.56+3.13 (+0.63%) ▲|LLY1,248.36-8.67 (-0.69%) ▼|LMT549.50-2.59 (-0.47%) ▼|LOW195.48-1.91 (-0.97%) ▼|LRCX278.52+14.58 (+5.52%) ▲|MA613.06-4.36 (-0.71%) ▼|MCD242.34-0.64 (-0.26%) ▼|MDLZ63.57-0.34 (-0.53%) ▼|MDT92.88-1.88 (-1.98%) ▼|META703.34-5.99 (-0.84%) ▼|MMM163.79-0.96 (-0.58%) ▼|MO74.23-0.88 (-1.17%) ▼|MRK144.60-1.35 (-0.93%) ▼|MS179.96-0.61 (-0.34%) ▼|MSFT534.15+5.10 (+0.96%) ▲|MU919.77+40.93 (+4.66%) ▲|NEE78.56-1.24 (-1.55%) ▼|NFLX69.68-0.86 (-1.21%) ▼|NKE36.84-0.30 (-0.79%) ▼|NOW143.89+1.92 (+1.35%) ▲|NVDA219.54+5.41 (+2.53%) ▲|ORCL130.69+2.46 (+1.91%) ▲|PEP132.38+0.89 (+0.68%) ▲|PFE29.30-0.29 (-0.96%) ▼|PG157.22-2.13 (-1.34%) ▼|PLTR196.03+10.00 (+5.38%) ▲|PM201.78-3.42 (-1.67%) ▼|QCOM173.83+1.72 (+1.00%) ▲|RTX191.84-2.09 (-1.08%) ▼|SBUX97.95+0.43 (+0.44%) ▲|SCHW90.19-1.77 (-1.92%) ▼|SO89.67-1.52 (-1.66%) ▼|SPG203.50-1.94 (-0.94%) ▼|T23.11-0.34 (-1.43%) ▼|TMO677.03-12.97 (-1.88%) ▼|TMUS157.62-1.48 (-0.93%) ▼|TSLA367.63+12.91 (+3.64%) ▲|TXN274.55-1.93 (-0.70%) ▼|UBER70.39+0.04 (+0.05%) ▲|UNH401.77+0.34 (+0.08%) ▲|UNP286.76-2.28 (-0.79%) ▼|UPS97.32-0.17 (-0.17%) ▼|USB58.21-0.53 (-0.89%) ▼|V401.95-0.67 (-0.17%) ▼|VZ44.11-0.68 (-1.52%) ▼|WFC82.17-1.71 (-2.03%) ▼|WMT118.35-0.47 (-0.39%) ▼|XOM177.58-1.40 (-0.78%) ▼|AAPL342.92-0.55 (-0.16%) ▼|ABBV284.42-1.00 (-0.35%) ▼|ABT103.77-1.12 (-1.07%) ▼|ACN231.93+2.25 (+0.98%) ▲|ADBE244.88-0.33 (-0.13%) ▼|AMAT423.98+14.69 (+3.59%) ▲|AMD548.48+19.73 (+3.73%) ▲|AMGN427.01-5.49 (-1.27%) ▼|AMT182.77-2.50 (-1.35%) ▼|AMZN262.97+12.97 (+5.19%) ▲|AVGO339.14+10.39 (+3.16%) ▲|AXP313.39-0.21 (-0.07%) ▼|BA191.44+1.23 (+0.64%) ▲|BAC50.53-0.71 (-1.38%) ▼|BKNG161.04-2.41 (-1.47%) ▼|BLK1,128.55-5.83 (-0.51%) ▼|BMY58.66-1.10 (-1.83%) ▼|BNY143.11-0.20 (-0.14%) ▼|BRK-B530.62-1.41 (-0.26%) ▼|C122.91-1.35 (-1.09%) ▼|CAT730.66-0.10 (-0.01%) ▼|CL93.04-1.07 (-1.14%) ▼|CMCSA21.72-0.19 (-0.84%) ▼|COF199.66-2.08 (-1.03%) ▼|COP144.69-1.82 (-1.24%) ▼|COST990.00+0.89 (+0.09%) ▲|CRM239.54-1.16 (-0.48%) ▼|CSCO107.35-0.04 (-0.04%) ▼|CVS91.22-1.14 (-1.23%) ▼|CVX223.64-1.35 (-0.60%) ▼|DE629.94-11.92 (-1.86%) ▼|DHR225.22-3.82 (-1.67%) ▼|DIS109.71-0.89 (-0.80%) ▼|DUK119.56-1.92 (-1.58%) ▼|EMR161.73+0.26 (+0.16%) ▲|FDX292.88-0.67 (-0.23%) ▼|GD341.62-2.61 (-0.76%) ▼|GE312.35-1.48 (-0.47%) ▼|GEV921.84+0.64 (+0.07%) ▲|GILD154.68-1.51 (-0.97%) ▼|GM82.42-1.54 (-1.83%) ▼|GOOG341.25+4.34 (+1.29%) ▲|GOOGL345.42+4.83 (+1.42%) ▲|GS881.36+0.10 (+0.01%) ▲|HD309.40-0.23 (-0.07%) ▼|HON211.09-0.33 (-0.15%) ▼|IBM236.12+3.98 (+1.71%) ▲|INTC94.58+4.73 (+5.26%) ▲|INTU321.82-3.33 (-1.02%) ▼|ISRG432.22+5.52 (+1.29%) ▲|JNJ252.70-2.86 (-1.12%) ▼|JPM335.60-4.12 (-1.21%) ▼|KO93.60-0.30 (-0.32%) ▼|LIN501.56+3.13 (+0.63%) ▲|LLY1,248.36-8.67 (-0.69%) ▼|LMT549.50-2.59 (-0.47%) ▼|LOW195.48-1.91 (-0.97%) ▼|LRCX278.52+14.58 (+5.52%) ▲|MA613.06-4.36 (-0.71%) ▼|MCD242.34-0.64 (-0.26%) ▼|MDLZ63.57-0.34 (-0.53%) ▼|MDT92.88-1.88 (-1.98%) ▼|META703.34-5.99 (-0.84%) ▼|MMM163.79-0.96 (-0.58%) ▼|MO74.23-0.88 (-1.17%) ▼|MRK144.60-1.35 (-0.93%) ▼|MS179.96-0.61 (-0.34%) ▼|MSFT534.15+5.10 (+0.96%) ▲|MU919.77+40.93 (+4.66%) ▲|NEE78.56-1.24 (-1.55%) ▼|NFLX69.68-0.86 (-1.21%) ▼|NKE36.84-0.30 (-0.79%) ▼|NOW143.89+1.92 (+1.35%) ▲|NVDA219.54+5.41 (+2.53%) ▲|ORCL130.69+2.46 (+1.91%) ▲|PEP132.38+0.89 (+0.68%) ▲|PFE29.30-0.29 (-0.96%) ▼|PG157.22-2.13 (-1.34%) ▼|PLTR196.03+10.00 (+5.38%) ▲|PM201.78-3.42 (-1.67%) ▼|QCOM173.83+1.72 (+1.00%) ▲|RTX191.84-2.09 (-1.08%) ▼|SBUX97.95+0.43 (+0.44%) ▲|SCHW90.19-1.77 (-1.92%) ▼|SO89.67-1.52 (-1.66%) ▼|SPG203.50-1.94 (-0.94%) ▼|T23.11-0.34 (-1.43%) ▼|TMO677.03-12.97 (-1.88%) ▼|TMUS157.62-1.48 (-0.93%) ▼|TSLA367.63+12.91 (+3.64%) ▲|TXN274.55-1.93 (-0.70%) ▼|UBER70.39+0.04 (+0.05%) ▲|UNH401.77+0.34 (+0.08%) ▲|UNP286.76-2.28 (-0.79%) ▼|UPS97.32-0.17 (-0.17%) ▼|USB58.21-0.53 (-0.89%) ▼|V401.95-0.67 (-0.17%) ▼|VZ44.11-0.68 (-1.52%) ▼|WFC82.17-1.71 (-2.03%) ▼|WMT118.35-0.47 (-0.39%) ▼|XOM177.58-1.40 (-0.78%) ▼|
15.1 C
New York
Monday, October 19, 2026

Tag: cell therapy

newssourceFORcompanycontentinformation1releasesmarket

New Progress — XellSmart Unveiled Phase I Results of Off-the-Shelf Parkinson’s Disease Cell Therapy at MDS & Completed Blinded Phase II Enrollment

SEOUL, South Korea and SHANGHAI, Oct. 18, 2026 /PRNewswire/ -- New clinical data for XellSmart's off-the-shelf cell therapy for Parkinson's Disease was presented at...

Vivacta Bio and Grit Bio Announce FDA Orphan Drug Designation for In Vivo CAR-T Therapy GT801 in Autoimmune Hemolytic Anemia

SHANGHAI, Oct. 17, 2026 /PRNewswire/ -- Vivacta Biotechnology (Shanghai) Co., Ltd. ("Vivacta Bio"), a company spun out of the in vivo CAR-T platform of...

Bioprocess Technology Market to Reach USD 134.06 Billion by 2035 – Credence Research

LONDON, Oct. 15, 2026 /PRNewswire/ -- The "Bioprocess Technology Market – Growth, Share, Opportunities & Competitive Analysis, 2025–2035" report has been added to the...

NEW YORK BLOOD CENTER ENTERPRISES APPOINTS MEGHAN DELANEY, DO, MPH, AS NEXT PRESIDENT & CHIEF EXECUTIVE OFFICER

Current President and CEO Christopher D. Hillyer, MD, to serve as Special Advisor to the Board of TrusteesNEW YORK, Oct. 12, 2026 /PRNewswire/ --...

T-MAXIMUM’s B7-H3-Targeted Allogeneic CAR-T MT027 Receives FDA Clearance for Phase 2 Study in Brain Metastases from Lung and Breast Cancer

BEIJING, Oct. 12, 2026 /PRNewswire/ -- T-MAXIMUM PHARMACEUTICAL ("T-MAXIMUM") today announced that the U.S. Food and Drug Administration (FDA) has cleared the company to...

First Patient Dosed in Phase III Perioperative Study of Cadonilimab (PD-1/CTLA-4) in Colon Cancer

HONG KONG, Oct. 10, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a...

US WorldMeds Receives the Sarcoma Foundation of America’s 2026 Vision of Hope Award

Company recognized for advancing treatment options in sarcoma and for embedding the patient advocacy perspective into its development and regulatory workLOUISVILLE, Ky., Oct. 9,...

Cell Culture Monitoring Biosensors Market to Reach USD 906.56 Million by 2032 – Credence Research

LONDON, Oct. 6, 2026 /PRNewswire/ -- The "Cell Culture Monitoring Biosensors Market – Growth, Share, Opportunities & Competitive Analysis, 2025–2032" report has been added...

Cell Culture Monitoring Biosensors Market to Reach USD 906.56 Million by 2032 – Credence Research

LONDON, Oct. 6, 2026 /PRNewswire/ -- The "Cell Culture Monitoring Biosensors Market – Growth, Share, Opportunities & Competitive Analysis, 2025–2032" report has been added...

Taiwan Biotech Delegation Showcases Regional Innovation in CDMO, Cell Therapy, and Biologics at BioJapan 2026

YOKOHAMA, Japan, Oct. 6, 2026 /PRNewswire/ -- Highlighting regional life sciences innovation, 17 Taiwanese biotech companies and research institutions are gathering at BioJapan 2026 (Oct....

Global Exosomes Market to Reach USD 2,250 Million by 2034 at 28.8% CAGR as Expanding Applications in Drug Delivery, Diagnostics, and Regenerative Medicine Fuel...

PUNE, India, Sept. 22, 2026 /PRNewswire/ -- The Global Exosomes Market was valued at USD 230.55 Million in 2025 and is projected to expand at a 28.8%...

Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference

SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced positive five-year data from its ongoing HOPE-2 Open-Label Extension (OLE) study of Deramiocel, the Company’s lead cell therapy candidate for Duchenne Muscular Dystrophy (DMD). The data will be presented at the Parent Project Muscular Dystrophy (PPMD) 2026 Annual Conference, taking place June 25-27, 2026, in Orlando, Florida, alongside previously reported results from the Company’s HOPE-3 Phase 3 trial.

Mesoblast Draws US$50 Million from Five-Year Non-Dilutive Facility

Optimized capital structure, retiring short-term maturing debt

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., June 19, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on June 18, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 140,860 shares of Iovance’s common stock to twenty-seven new, non-executive employees.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCell therapy

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers